Skip to main content
Premium Trial:

Request an Annual Quote

NCATS Skeptics

The US National Institutes of Health has fielded a lot of skepticism regarding the National Center for Advancing Translational Sciences. Many in the research and funding communities say drug discovery is best left to pharmaceutical and biotech companies and NIH should concentrate on its basic research mandate. As our sister publication GenomeWeb Daily News reported, NCATS recently signed a deal with three pharmaceutical companies to enable researchers to test drugs the companies discarded to see if they can be repurposed. Forbes contributor John LaMattina, former president of Pfizer R&D, is skeptical as to the chances of this program's success. "If pharmaceutical companies already have this covered, why are they agreeing to let the NIH have access to these compounds? Why not?" LaMattina says. "Basically, the NIH is providing free R&D for compounds that are no longer in development, despite the companies' best efforts. They have nothing to lose by letting the NIH sponsor this work." Maybe NIH will get lucky and find something, he adds, but even if that happens, this isn't really the best use of NIH's funding, given tight budgets.

At In the Pipeline, Derek Lowe says it's only a matter of time before everyone knows whether this project was a waste of time and money. However, he adds, even if NCATS succeeds in the drug discovery business, this isn't the most efficient way to do it. "I'd rather start with a compound that I know does what I want it to do, and then try to turn it into a drug (phenotypic screening)," Lowe says. "Starting with a compound that you know is a drug, but doesn't necessarily do what you want it to, is going to be tricky."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.